Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
Source: View publication →
In the phase Ia/b TRAVERSE trial, the off-the-shelf, CD70-targeted allogeneic CAR T-cell therapy ALLO-316 demonstrated a manageable safety profile and encouraging preliminary antitumor activity in heavily pretreated patients with advanced clear cell renal cell carcinoma, particularly those with high CD70 expression.
Key Findings
Study Design
Study Limitations
Clinical Significance
The TRAVERSE trial provides the first robust clinical proof-of-concept that an allogeneic, off-the-shelf CAR T-cell therapy can exert meaningful and durable antitumor activity in a solid tumor. The manageable safety profile and encouraging 31.3% response rate in CD70-high tumors mark a significant milestone for patients with heavily pretreated, refractory clear cell renal cell carcinoma who have exhausted standard immune checkpoint and VEGF inhibitors.
Historical Context
While autologous chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of hematologic malignancies, their success in solid tumors has been hindered by the immunosuppressive tumor microenvironment, poor T-cell persistence, and manufacturing delays. ALLO-316 was developed to overcome these barriers by utilizing novel technology to target CD70, an immunoregulatory protein highly expressed in clear cell renal cell carcinoma but limited in normal tissues. Furthermore, the therapy is engineered to simultaneously eliminate CD70-positive host alloreactive T cells, thereby resisting immune rejection and paving the way for scalable, 'off-the-shelf' allogeneic cell therapies in solid oncology.
Guided Discussion
High-yield insights from every perspective
What is the pathophysiological rationale for targeting CD70 in clear cell renal cell carcinoma (ccRCC), and how does the classic genetic mutation in ccRCC drive the expression of this specific antigen?
Key Response
In clear cell RCC, the loss of the von Hippel-Lindau (VHL) tumor suppressor gene leads to the stabilization and accumulation of Hypoxia-Inducible Factors (HIFs). The HIF pathway directly upregulates the expression of CD70 on the cell surface, making it a highly specific, biologically driven target for therapies like ALLO-316 in this malignancy.
When monitoring a patient who has received an allogeneic CAR T-cell therapy like ALLO-316, how does the anticipated complication profile differ from traditional autologous CAR T-cell therapy, and what specific new immunological risks must be managed?
Key Response
While both autologous and allogeneic CAR T-cells can cause Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), allogeneic 'off-the-shelf' products introduce the risk of Graft-Versus-Host Disease (GVHD), necessitating gene editing (like TCR knockout) to mitigate this. Furthermore, profound and prolonged lymphodepletion is required to prevent Host-Versus-Graft rejection, significantly increasing the risk for opportunistic infections.
The TRAVERSE trial noted the best responses in patients with high CD70 expression. Given the known antigen heterogeneity and hostile microenvironment in solid tumors, what are the primary mechanisms of CAR-T resistance in this setting, and how might advanced engineering strategies address them?
Key Response
Resistance in solid tumors like ccRCC is driven by antigen escape (heterogeneous or downregulated CD70 expression) and an immunosuppressive tumor microenvironment (TME). Future strategies to overcome this include dual-targeting CARs to prevent antigen escape, or 'armored' CARs engineered to secrete pro-inflammatory cytokines (e.g., IL-12) to remodel the TME and enhance T-cell persistence and tumor infiltration.
If ALLO-316 progresses to FDA approval, how will the availability of an 'off-the-shelf' allogeneic CAR T-cell product disrupt our current sequencing of therapies for relapsed/refractory ccRCC compared to standard autologous cell therapies?
Key Response
Currently, heavily pretreated ccRCC lacks highly durable options post-IO and post-VEGF TKIs. An allogeneic product eliminates the manufacturing delays (vein-to-vein time) and bridging therapy needs inherent to autologous CAR T-cells. This logistical advantage allows rapid treatment of patients with aggressive, rapidly progressing disease who otherwise might not survive the autologous manufacturing process, shifting cellular therapy from a last-resort option to a more accessible, practical early-salvage therapy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In early-phase trials of allogeneic CAR T-cells, optimizing both the CAR-T dose and the lymphodepletion regimen is critical. What are the methodological challenges of using a traditional 3+3 dose-escalation design in this context, and why might a Bayesian or bivariate continuous reassessment method be superior?
Key Response
A standard 3+3 design assumes a monotonic dose-toxicity relationship and optimizes a single agent's dose. In allogeneic CAR-T trials, toxicity and efficacy are driven by a two-dimensional matrix: the lymphodepletion intensity (to prevent host rejection) and the CAR-T dose itself. Bivariate Bayesian models can dynamically model these complex dose-toxicity and dose-efficacy relationships, allowing for simultaneous optimization and better utilization of all patient data without stalling escalation due to isolated, non-dose-limiting toxicities.
As a reviewer evaluating the TRAVERSE trial results, what are the primary threats to the long-term validity of the efficacy claims regarding allogeneic CAR T-cells, specifically focusing on cellular kinetics and the conditioning regimen?
Key Response
A critical reviewer would flag that allogeneic CAR-T cells classically suffer from poor long-term persistence due to eventual host-mediated immune rejection (allo-rejection). Therefore, early 'encouraging preliminary activity' may not translate to durable progression-free survival. Furthermore, the intensive lymphodepletion required (often incorporating agents like anti-CD52) carries a profound risk of prolonged cytopenias and fatal opportunistic infections, which could confound overall survival in a larger Phase III trial.
Considering current NCCN guidelines for advanced ccRCC primarily recommend VEGF TKIs, immunotherapy, and HIF-2alpha inhibitors for refractory disease, what level of evidence and trial endpoints would be required for the committee to endorse a CD70-directed allogeneic CAR T-cell therapy as a standard later-line option?
Key Response
Current NCCN guidelines prioritize clinical trial enrollment or agents like tivozanib or belzutifan (HIF-2alpha inhibitor) in the heavily pretreated setting. For ALLO-316 to be incorporated into guidelines, a randomized Phase III trial demonstrating a statistically significant and clinically meaningful improvement in Overall Survival (OS) or Progression-Free Survival (PFS) compared to active standard-of-care is required, along with validation of a companion diagnostic for CD70 expression threshold and a tolerable long-term safety profile regarding infections.
Clinical Landscape
Noteworthy Related Trials
CheckMate 025
Tested
Nivolumab
Population
Patients with previously treated advanced clear-cell RCC
Comparator
Everolimus
Endpoint
Overall survival
CheckMate 214
Tested
Nivolumab plus Ipilimumab
Population
Previously untreated advanced clear-cell RCC
Comparator
Sunitinib
Endpoint
Overall survival and progression-free survival
KEYNOTE-426
Tested
Pembrolizumab plus Axitinib
Population
Previously untreated advanced clear-cell RCC
Comparator
Sunitinib
Endpoint
Overall survival and progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis